Outset Medical, Inc. (NASDAQ:OM) announced that its Chair and CEO, Leslie Trigg, conducted a sale of company common stock on May 15, 2026. Specifically, Ms. Trigg sold 3,445 shares of the firm's common stock, amounting to a total value of $12,746. The transaction was executed at an individual price point of $3.70 per share.
The nature of this divestiture has been clarified as a 'sell to cover' action. This specific type of sale is mandatory and was utilized solely to satisfy tax withholding obligations. These tax requirements arose in connection with the vesting of various common stock units that were originally granted to Ms. Trigg on two separate dates: January 12, 2024, and June 10, 2025. It is important to note that this specific transaction does not represent a discretionary trade made by the reporting executive.
Following the execution of this sale, corporate filings indicate that Ms. Trigg's direct holdings in Outset Medical common stock amount to 98,874 shares. This reported balance incorporates an adjustment from a previous filing on February 19, 2026, which had contained an administrative error regarding the number of shares sold for tax withholding purposes, stating 3,361 shares when the correct figure was 3,384 shares.
In addition to her direct holdings, Ms. Trigg maintains indirect ownership through family trusts and investment vehicles. She indirectly holds 41,666 shares via the Trigg 2002 Rev Trust and an additional 584 shares through the Trigg Family Trust.
The timing of this reported sale occurs amidst notable market movement for Outset Medical stock. Over the past year, the stock has experienced a decline exceeding 80%. Currently, the stock trades at $3.86, which is near its 52-week low of $3.00.
More broadly, recent corporate developments provide context for Outset Medical's market activity. The company reported its Q1 2026 earnings, during which time revenue saw a 6% decrease, settling at $27.9 million compared to the first quarter of 2025. Despite this reduction in quarterly revenue, management provided full-year guidance, projecting total revenue between $125 million and $130 million.
The company's strategic focus on key areas such as innovation and cybersecurity has been highlighted as a potential contributing factor to the market's positive reaction. These developments were further underscored by the stock experiencing measurable increases during both regular trading sessions and after-hours aftermarket trading periods. Management representatives emphasized an ongoing commitment to long-term growth strategies and solidifying the company's market position, leading investors and analysts to closely monitor how these strategic initiatives will influence future performance.
Risks
- The stock has declined over 80% in the past year, indicating potential market skepticism regarding current valuation.
- Q1 revenue saw a 6% decrease compared to the prior year, suggesting immediate operational headwinds despite long-term guidance.
- Management's reliance on strategic initiatives (innovation and cybersecurity) suggests future performance is contingent upon successful execution of these plans.
More from Insider Trading